Anti-TNF therapy of ankylosing spondylitis in clinical practice. Results from the Czech national registry ATTRA

To estimate efficacy, safety and adherence to therapy of ankylosing spondlitis (AS) patients included in the Czech National Registry ATTRA, and to look for predictive factors for therapy discontinuation. Patients were included according to the guidelines of the Czech Society for Rheumatology, which...

Full description

Saved in:
Bibliographic Details
Published in:Clinical and experimental rheumatology 2009-11, Vol.27 (6), p.958-963
Main Authors: PAVELKA, K, FOREJTOVA, S, STOLFA, J, CHROUST, K, BURESOVA, L, MANN, H, VENCOVSKY, J
Format: Article
Language:English
Subjects:
Antibodies, Monoclonal - adverse effects
Antibodies, Monoclonal - therapeutic use
Antirheumatic Agents - adverse effects
Antirheumatic Agents - economics
Antirheumatic Agents - therapeutic use
Arthritis, Rheumatoid - therapy
Biological and medical sciences
Cost of Illness
Czech Republic
Diseases of the osteoarticular system
Diseases of the spine
Drug Costs
Female
Humans
Inflammatory joint diseases
Kaplan-Meier Estimate
Male
Medical sciences
Patient Compliance
Registries
Regression Analysis
Severity of Illness Index
Spondylitis, Ankylosing - economics
Spondylitis, Ankylosing - therapy
Time Factors
Treatment Outcome
Tumor Necrosis Factor-alpha - antagonists & inhibitors
Tumor Necrosis Factor-alpha - therapeutic use
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To estimate efficacy, safety and adherence to therapy of ankylosing spondlitis (AS) patients included in the Czech National Registry ATTRA, and to look for predictive factors for therapy discontinuation. Patients were included according to the guidelines of the Czech Society for Rheumatology, which involve failure of previous therapy, BASDAI >4, and CRP >10 mg/l. Only patients with anti-TNF administered for the first time were analysed. Adherence to therapy was evaluated using Kaplan-Meier analysis and results were presented as cumulative survival. Comparison with data on patients with rheumatoid arthritis (RA) followed in the same registry was made. 310 of AS patients who had reached at least 1 year as well as those who discontinued the treatment before this time point were analysed. Drug survival was longer in patients with AS than in those with RA: 84% vs. 78% and 72% vs. 49% after 1 and 3 years of treatment. Significant risk factors for treatment discontinuation were female gender (RR 2.22, p=0.001) and CRP (RR 1.33, p=0.025). The proportion of patients with BASDAI
ISSN:0392-856X
1593-098X